## Advancing Science for the Health of Women

## Janine Austin Clayton, M.D.

NIH Associate Director for Research on Women's Health
Director, Office of Research on Women's Health
National Institutes of Health
Government-University-Industry Research Roundtable Webinar
National Academies of Sciences, Engineering, and Medicine
March 23, 2018

NIH $>$ National Institutes of Health
Office of Research on Women's Health
orwh.od.nih.gov \| \#SABV \| @NIH_ORWH

## NIH Office of Research on Women's Health (ORWH)



## Our Mission:

1. Enhance and expand women's health research
2. Include women and minority groups in clinical research
3. Promote career advancement for women in STEM

## (ORWH)

NIH Office of Research on Women's Health


## Our Mission:

1. Enhance and expand women's health research
2. Include women and minority groups in clinical research
3. Promote career advancement for women in STEM


Rep. Louise Slaughter (D-NY) August 14, 1929 March 16, 2018

- Co-authored the Violence Against Women Act
- Dedicated first $\$ 500$ million in funds to breast cancer research
- First female Chair of the House Rules Committee


## Circle of Partners in Human Health



## Circle of Partners in Human Health



## Outline

- Women's Health: U.S. vs. Peer Countries
- Mission-based Solutions
- Enhance and Expand Women's Health Research
- Policy, Programs, and Partnerships
- Inclusion of Women and Minority Groups in Clinical Research
- Promote Career Advancement for Women in STEM
- Strategic Plan for the Future $-21^{\text {st }}$ Century Cures



## Life expectancy has been increasing worldwide: How does the U.S. compare?

## Men



Women


NIH
National Institutes of Health Office of Research on Women's Health

## Maternal mortality is rising in the U.S. as it declines elsewhere

Deaths per 100,000 live births


NIH
National Institutes of Health Office of Research on Women's Health Global Burden of Disease Study 2015. The Lancet 388 (10053): 1775-1812.

## The opioid crisis is a women's health issue

- From 2005 to 2015, opioid-related inpatient hospital stays increased $55 \%$ in men and $75 \%$ in women.
- In 2014, women had higher rates of opioid-related inpatient hospital stays in most states.
- Between 1999 and 2015, death from Rx opioid overdoses increased $471 \%$ in women and $218 \%$ in men.


Higher rate of opioid-related inpatient hospital stays in 2014

## How Does NIH/ORWH Address Those Trends?



## Rigor \& Reproducibility

NOT-OD-15-103: Enhancing
Reproducibility through Rigor and Transparency-6/2015

## Sex as a Biological Variable

## "Science isn't science if it isn't reproducible"*

## How did we get here?

- Overreliance on male animals and cells
- Inattention to sex effects
- Lack of transparency
- Inconsistent reporting of sex-specific findings in publications


## Consequences

- Incomplete knowledge base
- Risk of erroneous conclusions
- Risk of harm \& toxicity surprises
- Failure to maximize ROI
- Erosion of public trust


## Enhancing Reproducibility: Rigor and Transparency

## NEW GRANT GUIDELINES

what you need to know

WHY UPDATE THE GUIDELINES?
The updatos focus on four areas deemed important for enhancing rigor and transparency:

## WHAT ARE THE UPDATES?

UPDATES TO RESEARCH STRATEGY GUIDANCE


The research strategy is where you discuss the significance, innovation, and approach of your research plan. Let's look at an R01, for example:


The new research strategy guidelines require that you - State the strengths and weakness of published research or preliminary data crucial to the support of your spplication
-Describe how your experimental design and methods - Dill accibieve how yourt and unbiased results

- Explain how biological variables, such as sex, are factored into research design and provide justification if only one sex is used

NEW ATTACHMENT FOR AUTHENTICATION OF KEY BIOLOGICAL AND/OR CHEMICAL RESOURCES
From now on, you must briefly describe methods to ensure the identity and validity of key biological and/or chemical resources used in the proposed studies.

These include, but are not limited to:
CELL LINES $\rightarrow$ SPECIALTY CHEMICALS
ANTIBODIES OTHER BIOLOGICS

## NEW REVIEWER GUIDELINES

Here are the additional criteria the reviewers will be asked to use:
Standard laboratory reagents that are not expected to vary do not need to be included in the plan Examples are buffers and other common biologicals or chemicals.


Is there a strong scientific premise for the project?
Have the investigators presented adequate plans to address
relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
 relevant biological variables

Authentication of key
biological and/or chemical tesource

DESIGN Rigorous experimen-
tal design for robust and unbiased results

## Sex As a Biological Variable (SABV) Policy

"NIH expects that sex as a biological variable will be factored into research designs, analyses, and reporting in vertebrate animal and human studies."

NOT-OD-15-102*: Consideration of Sex as a Biological Variable in NIH-funded Research
*Effective date: January 25, 2016
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-102
Videocast of Oct. 26-27, 2017 SABV Workshop available online: https://commonfund.nih.gov/sexdifferences/workshop

## SABV Next Steps: Intentional Integration

 Sex/Gender Influences on Health and DiseaseAccounting for Sex as a Biological Variable in Design, Analysis, Reporting

Preclinical Studies Phase I, II, III, IV Clinical Trials

Education | Health Policy | Health Care

## Sex/gender-specific reporting lags behind inclusion

## Enrollment Trend for Males and Females in NIH-Defined Clinical Research (Excluding Sex-Specific Studies)



Source: Report of the NIH Advisory Committee on Research on Women's Health for FY13-14. Additional inclusion data available at https://orwh.od.nih.gov/.

Reporting of Sex/Gender-Specific Results from NIH-Funded Phase III Clinical Trials, 1995-2010


Foulkes MA. 2011. After inclusion, information and inference: reporting on clinical trials results after 15 years of monitoring inclusion of women. Journal of Women's Health 20 (6): 829-836.

## How ORWH Achieves Results



Specialized Centers of Research (SCOR) on Sex Differences Program

## Supplemental Funding

IC Women's Health Research and
Co-Funding

## ORWH Funding History \& FY17 Extramural Award Profile



FY17 Extramural Awards
(as \% of Extramural Budget)

## Funding Opportunity: Specialized Centers of Research (SCOR) on Sex Differences

- To foster interdisciplinary research on etiology, treatment \& prevention of diseases that affect women
- FY12-FY17: 11 SCOR Awards across 6 ICs
- NIA, NIAMS, NIDDK, NIMH, NICHD \& NIDA
- FY 18: Specialized Centers of Research Excellence (SCORE) on
- Career Enhancement Core (CEC) now required - to meet career enhancement needs of translational science in the study of sex differences



## New Findings from Yale SCOR

 Investigator
## When it comes to addiction, sex matters

Addicts' cravings have different roots in men and women. Read the new study on brain imaging from Yale School of Medicine. (PDF, 327 KB)
Kober H., Lacadie C.M., Wexler B.E., Malison R.T., Sinha R., Potenza M.N. 2016. Brain activity during cocaine craving and gambling urges: an fMRI study. Neuropsychopharmacology 41 (2): 628-637.

## FY17 ORWH Sex \& Gender Administrative Supplements

## Preclinical



ORIP
Do gut microbiota affect sex differences in Alzheimer's disease?

Clinical


NIDA
Gender diffs. in mechanisms of recovery from opioid use disorder \& anxiety

Preclinical + Clinical


Does obesity in HIV-infected men \& women ( $\uparrow$ in women) increase risk of CVD / diabetes? A study of markers in adipose tissue.

New FOA (PA-18-658) Applications due March 26, 2018

U3 Administrative Supplement: Research on Understudied Issues
Underreported Information

## Underrepresented Populations of Women

- 1 yr. supplemental funding
- \$1.7 M funded for 15 U3 applications in FY17
- Examples:
$\checkmark$ MsFLASH Clinical Trials Network: living a healthy menopause
$\checkmark$ Impact of cocaine and polydrug use on cranial small vessel disease
$\checkmark$ Ethnic differences in outcomes and treatment barriers after sexual assault


New FOA (PA-18-676) Applications due April 16, 2018

## ORWH Co-funding in Targeted Research Areas

- Brain Research Through Advancing Innovative Neurotechnologies ${ }^{\circledR}$ (BRAIN) Initiative
- NIH Pain Consortium \& Centers of Excellence in Pain Research
- Bladder Health, Lower Urinary Tract Symptoms, and Chronic Pelvic Pain Research

(Lab of Neuro Imaging and Martinos Center for Biomed. Imaging, Human Connectome Project Consortium)
- Diabetes Prevention Program \& Diabetes Prevention Program Outcomes Study
- Osteoarthritis Initiative



## It Takes a Village...



## Publishers

Pharmaceutical Industry

## Manufacturers

## Good News: Decline in Omission of Sex

## Bad News: Male Bias Persists



Will et al. 2017. Problems and progress regarding sex bias and omission in neuroscience research. eNeuro 4 (6): e0278-17.2017.

Primary Cell Culture Studies in ASM Journals - 2016


Potluri et al. 2017. Sex reporting in preclinical microbiological and immunological research. $m B i o$ 8: e01868-17.

## Some journals are taking proactive steps to enforce changes in reporting practices



## SABV Partnerships and Pharma

## FDA U.S. FOOD \& DRUG ADMINISTRATION

FDA Office of Women's Health www.fda.gov/womenshealthresearch


# Getting the Dosage Right 

## The New Hork Eimes

## Health

## The Drug-Dose Gender Gap


"This is not just about Ambien - that's just the tip of the iceberg," said Dr. Janine Clayton, director for the Office of Research on Women's Health at the National Institutes of Health. "There are a lot of sex differences for a lot of drugs, some of which are well known and some that are not well recognized." ... "For example, Seldane, an antihistamine, and the gastrointestinal drug Propulsid both triggered a potentially fatal heart arrhythmia more often in women than in men. Many drugs still on the market cause this arrhythmia more often in women, including antibiotics, antipsychotics, anti-malarial drugs and cholesterol-lowering drugs, Dr. Clayton said."

## Getting the Dosage Right

## ©be Avew llork Eimes


"This is not just about Ambien - that's just the tip of the iceberg," said Dr. Janine Clayton, director for the Office of Research on Women's Health at the National Institutes of Health. "There are a lot of sex differences for a lot of drugs, some of which are well known and some that are not well recognized." ... "For example, Seldane, an antihistamine, and the gastrointestinal drug Propulsid both
triggered a potentially fatal heart arrhythmia more often in antihistamine, and the gastrointestinal drug Propulsid both
triggered a potentially fatal heart arrhythmia more often in women than in men. Many drugs still on the market cause this arrhythmia more often in women, including antibiotics, antipsychotics, anti-malarial drugs and cholesterol-lowering drugs, Dr. Clayton said."

Health

Drugs With Different Effects in Men and Women

## Ambien

(zolpidem)

- W: stroke protection
- M: MI protection

Antihistamines

- Dose $50 \%$ less in women arrhythmias


## Manufacturing: Turning Discovery into Innovation

## Related to Sex Differences Manufacturing: Turning Discovery into Innovation

- MRI: imaging sex differences



## Related to Sex Differences Manufacturing: Turning Discovery, into Innovation

- MRI: imaging sex differences
- Pregnant crash-test dummies

```
"Linda" by Volvo, a virtual pregnant crash-test dummy designed in 2002 by engineer Laura Thackray. "Linda" models the effects of high-speed impact on the womb, placenta, and fetus.
```


## Related to Sex Differences Manufacturing: Turning Discovery into Innovation

- MRI: imaging sex differences
- Pregnant crash-test dummies
- mHealth Innovations



## Women in Biomedical Careers



## Women in STEM: Diversity decreases along the biomedical career path

Figure 1. Gender Shares of Total and STEM Jobs, 2015


Source: OCE calculations using American Community Survey public-use microdata.
Note: Estimates are for employed persons age 16 and over.

## Women in STEM: Diversity decreases along the biomedical career path

Figure 2. Share of Workers in STEM Jobs by Gender and
Educational Attainment, 2015


Source: OCE calculations using American Community Survey public-use microdata. Note: Professional degrees include medical, dental, veterinary, and law degrees. Estimates are for employed persons age 16 and over

NIH
National Institutes of Health Office of Research on Women's Health

## BIRCWH (Building Interdisciplinary Research Careers in Women's Health)

- Mentored career-development to promote recruitment, retention \& advancement of careers in women's health
- RFA-OD-15-001 and RFA-OD-16-013
- 8 ICs: NICHD, NIAID, NIAAA, NIDA, NIDCR, NCI, NIA, NIAMS
- 20 BIRCWH Programs were funded in FY17
- Selected topics:
$\checkmark$ reproductive biology
$\checkmark$ cancer
$\checkmark$ depression, addiction, adverse childhood experiences
$\checkmark$ neuro-immune interactions
$\checkmark$ HIV-related
$\checkmark$ cardiometabolic risk burden
$\checkmark$ urinary microbiome in health \& disease



## NIH Working Group on Women in Biomedical Careers

- Funded the Causal Factors \& Interventions RFA
- 14 research grants investigating a range of obstacles facing women at all stages of the career pipeline
- \$16.8M over 4 years, with support from 11 ICs \& 4 Offices in OD
- Well over 100 papers published
- Work-life integration policies
- Women of Color Research Network (WoCRN)
- 4 regional chapters: DC, IN, MD, NC
- Over 500 members and growing
- https://womeninscience.nih.gov/women-of-color/


## Linkedin.



Dr. Lisa Barnes, Rush University, gave the NIH Director's WALS presentation on Feb. 28, 2018.

## Adjusting Our Courrse into the Future

- Rapid advancement of science \& technology
- Evolving public health needs
- Mandates of the 21st Century Cures Act


## NIH Inclusion Policy for Clinical Research Recently Amended, with backing from the $21^{\text {st }}$ Century Cures Act (Sec. 2053)

- Requires reporting of "valid analyses" on sex/gender \& race/ethnicity inclusion data to ClinicalTrials.gov after completion of applicable NIH-defined Phase III clinical trials
- Valid Analyses: stratified analyses exploring how well intervention works among sex/gender \& racial/ethnic groups
- Applicable Clinical Trials: in general, trials
investigating FDA-regulated therapeutics, biologics \& devices
- Applies to all new, competing grants \& cooperative


See: NOT-OD-18-014
More information: https://grants.nih.gov/grants/funding/lifespan/lifespan.htm

## Inclusion Across the Lifespan Policy


videos!

## The Future of Women's Health

Previous Framework: Women's Health


Current Framework: Health of Women


The US Department of Health and Human Services defines women's health as "diseases and conditions that affect women...all health concerns experienced by women across the lifespan and in the social context of their lives"


NIH National Institutes of Health Office of Research on Women's Health

## NIH Vision and ORWH Mission Putting Science to Work for the Health of Women

Sex and gender influences are integrated into the biomedical research enterprise; every disease prevention and treatment tailored to her own needs, circumstances and goals; and women in science reach their full potential.

To enhance research related to diseases, disorders and conditions affecting women; to help ensure that women are appropriately represented in biomedical research supported by the NIH; and to improve the advancement of women in biomedical careers.

# Looking to the Future: Draft Trans-NIH Strategic Priorities for Women's Health Research 

Turning Discovery into Health - Advancing the Health of Women


## Trans-NIH Strategic Plan Objectives

## Tactics

## $45^{\text {th }}$ Meeting of the ACRWH is April 18

- 9am-1:30pm, Building 31, 6C/Room 10
- Agenda includes:
- Director's Report
- Legislative \& $21^{\text {st }}$ Century Cures Act Update (Ms. Paris Watson, ORWH)
- Trans-NIH Strategic Plan for Women's Health Research (Dr. Margaret Bevans, ORWH)
- Urinary Tract Infection: Complexity Results from Diversity at the Bacterial-Host Interface (Dr. Scott Hultgren, Wash. U.)
- Inclusion of Pregnant and Lactating Women in Research (Dr. Diana Bianchi, NICHD)
- Please join us!



## Leveraging the Network to Advance Women in Science

## Wednesday, May 16, 2018

1:00-4:00 pm
NIH Main Campus
Lister Hill Auditorium
NIH Community Speaker Address: Kay Lund, Ph.D.
Academic Community Speaker Address: Daniel Ford, M.D., M.P.H, Navigating the Early Years to a Satisfying Career (tentative)

Women in STEM Speaker Address: Rachelle Heller, Ph.D.
New! SCatalytic Connections: "Speed" Networking


NIH National Institutes of Health Office of Research on Women's Health


## ORWH Newsletter



Director's
Corner


To receive the ORWH newsletter, send an email to ORWHINFO@mail.nih.gov with the subject line "Subscribe me to ORWH newsletter"

# Connect With Us 

NIH.gov/women
Y
@NIH_ORWH
Y
@JanineClaytonMD
( NIHORWH

